Quality by Design and Process Analytical Technology in Pharmaceutical Development: A Framework for Optimised Drug Product Manufacturing

Abstract

Quality by Design (QbD) and Process Analytical Technology (PAT) have transformed pharmaceutical development from an empirical, trial-and-error discipline into a systematic, science- and risk-based paradigm centred on a mechanistic understanding of formulation and process behaviour. This review synthesises literature published between 2011 and 2022 on the principles, applications and integration of QbD and PAT across the pharmaceutical product lifecycle. The fundamentals of QbD, including the Quality Target Product Profile, Critical Quality Attributes, Critical Material Attributes, Critical Process Parameters, Quality Risk Management, Design of Experiments, design space and control strategy, are examined alongside the PAT tools — near-infrared and Raman spectroscopy, focused beam reflectance measurement, acoustic and torque sensing, terahertz and optical coherence tomography imaging, and machine vision — that operationalise real-time process understanding. A year-wise review of representative studies traces the evolution of QbD-PAT integration from early spectroscopic feasibility studies to fully instrumented continuous manufacturing lines and, more recently, to artificial-intelligence-enabled digital twins. Applications across granulation, blending, compression, coating, sterile manufacturing, liquid and semi-solid formulations, and continuous manufacturing are discussed, together with the benefits (improved quality, reduced variability, fewer manufacturing failures, cost and time efficiency) and the persistent challenges of data management, instrumentation cost, and regulatory validation. The review concludes that the convergence of QbD, PAT, Industry 4.0 and predictive analytics is steering pharmaceutical manufacturing toward real-time quality assurance and represents the most credible route to consistently safe, effective and affordable medicines.